Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 Mar 28;23(12):2234-2245.
doi: 10.3748/wjg.v23.i12.2234.

Association between COX-2 -1195G>A polymorphism and gastrointestinal cancer risk: A meta-analysis

Xiao-Wei Zhang  1 , Jun Li  1 , Yu-Xing Jiang  1 , Yu-Xiang Chen  1
Affiliations
Meta-Analysis

Association between COX-2 -1195G>A polymorphism and gastrointestinal cancer risk: A meta-analysis

Xiao-Wei Zhang et al. World J Gastroenterol. .

Abstract

Aim: To perform a meta-analysis to investigate the association between cyclooxygenase-2 (COX-2) -1195G>A gene polymorphism and gastrointestinal cancers.

Methods: Publications related to the COX-2 -1195G>A gene polymorphism and gastrointestinal cancers published before July 2016 were retrieved from PubMed, EMBASE, Web of Science, China Biological Medicine Database, China National Knowledge Infrastructure, and CQVIP Database. Meta-analysis was performed using Stata11.0 software. The strength of the association was evaluated by calculating the combined odds ratios (ORs) and the corresponding 95%CIs. The retrieved publications were excluded or included one by one for sensitivity analysis. In addition, the funnel plot, Begg's rank correlation test, and Egger's linear regression method were applied to analyse whether the included publications had publication bias.

Results: A total of 24 publications related to the COX-2 -1195G>A gene polymorphism were included, including 28 studies involving 11043 cases and 18008 controls. The meta-analysis results showed that the COX-2 -1195G>A gene polymorphism significantly correlated with an increased risk of gastrointestinal cancers, particularly gastric cancer (A vs G: OR = 1.35; AA/AG vs GG: OR = 1.54; AA vs GG/AG: OR = 1.43; AA vs GG: OR = 1.80; AG vs GG: OR = 1.35). Compared to the Caucasian population in America and Europe, the COX-2 -1195G>A gene polymorphism in the Asian population (A vs G: OR = 1.30; AA/AG vs GG: OR = 1.50; AA vs GG/AG: OR = 1.35; AA vs GG: OR = 1.71; AG vs GG: OR = 1.37) significantly increased gastrointestinal cancer risk. The sensitivity analysis (P < 0.05) and the false positive report probability (P < 0.2) confirmed the reliability of the results.

Conclusion: The results showed that the COX-2 -1195G>A gene polymorphism might be a potential risk factor for gastrointestinal cancers. Further validation by a large homogeneous study is warranted.

Keywords: -1195G>A; COX-2; Gastrointestinal cancer; Meta-analysis; Polymorphism.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Flow chart of literature inclusion and exclusion.
Figure 2
Figure 2
Forest plot of the stratified analysis of the COX-2 -1195G>A dominant model (AA/AG vs GG) and susceptibility to gastrointestinal cancers in different tumour types.
Figure 3
Figure 3
Forest plot of stratified analysis of the COX-2 -1195G>A dominant model (AA/AG vs GG) and gastrointestinal cancer susceptibility in different populations.
Figure 4
Figure 4
Analysis of the influence of a single study on the total combined OR in the dominant model (AA/AG vs GG).
Figure 5
Figure 5
Cumulative meta-analysis of the COX-2 -1195G>A polymorphism and gastrointestinal cancer susceptibility in the dominant model (AA/AG vs GG).
Figure 6
Figure 6
Begg’s funnel plot of the publication bias in the COX-2 -1195G>A dominant model (AA/AG vs GG).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Abdelfatah E, Kerner Z, Nanda N, Ahuja N. Epigenetic therapy in gastrointestinal cancer: the right combination. Therap Adv Gastroenterol. 2016;9:560–579. - PMC - PubMed
    1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. - PubMed
    1. Rahbari M, Rahbari N, Reissfelder C, Weitz J, Kahlert C. Exosomes: novel implications in diagnosis and treatment of gastrointestinal cancer. Langenbecks Arch Surg. 2016;401:1097–1110. - PubMed
    1. Karimi Kurdistani Z, Saberi S, Tsai KW, Mohammadi M. MicroRNA-21: Mechanisms of Oncogenesis and its Application in Diagnosis and Prognosis of Gastric Cancer. Arch Iran Med. 2015;18:524–536. - PubMed
    1. Khatkov IE, Kagramanova AV, Zakharzhevskaya NB, Babikova EA, Generozov EV, Shcherbakov PL, Parfenov AI. [Current principles in the screening, diagnosis, and therapy of colorectal cancer] Ter Arkh. 2016;88:90–96. - PubMed

Publication types